Neurogamma (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble form of thiamine that easily enters cells and is converted to thiamine pyrophosphate, the active co‑enzyme. This enhances the activity of transketolase, reduces the accumulation of harmful metabolites, and helps protect nerves from oxidative stress.

The appropriate dose of Neurogamma is determined by the prescribing healthcare professional based on the individual’s health status, age, and therapeutic goals. Patients should follow the dosage instructions provided by their prescriber and not adjust the amount on their own.

Safety data for Neurogamma in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To order Neurogamma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Neurogamma combines benfotiamine, a highly bioavailable thiamine derivative, with pyridoxine hydrochloride, a stable form of vitamin B6. This dual formulation offers enhanced cellular uptake compared with standard thiamine or pyridoxine tablets, potentially providing more effective support for nerve health and metabolic pathways.

Neurogamma should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Neurogamma is taken orally, usually with water. The tablet or capsule should be swallowed whole and not chewed or crushed unless directed otherwise by a healthcare professional.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, liver enzyme elevations, and rare skin conditions like Stevens‑Johnson syndrome. Any signs of severe hypersensitivity or organ dysfunction should prompt immediate medical evaluation.

Individuals with known hypersensitivity to benfotiamine, pyridoxine, or any excipients in the formulation should avoid Neurogamma. Additionally, patients with severe renal impairment or those taking medications that may interact significantly should consult a healthcare professional before use.